Opexa Therapeutics OPXA Positive Tovaxin Data

September 8, 2009 - Shares of Opexa Therapeutics, Inc. (OPXA) are surging in pre market as the company released positive trial data this morning. OPXA stock is trading at $2.72 Up 78%.


Opexa Reports Additional Favorable Data with Tovaxin® for Multiple Sclerosis


Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). This analysis evaluated patients with an annualized relapse rate of one or greater at study entry (ARR≥1). More than 83% of the Tovaxin-treated group (n=85) remained relapse free at one year and the annualized relapse rate after treatment decreased to 0.20, a 42% reduction compared to placebo.

Full Article


For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free